{
  "docId": "019de076-4f8b-70c9-adf8-0b3abb8c1303",
  "docSlug": "1af2d4156bf2490b3ac2801b5487abdf",
  "documentTitle": "Larimar Therapeutics | Investor Presentation Deck | 44 slides",
  "authorId": "larimar-therapeutics",
  "authorName": "Larimar Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 38,
  "pageCount": 44,
  "prevPage": 37,
  "nextPage": 39,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4f8b-70c9-adf8-0b3abb8c1303/38",
  "deckHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303",
  "deckJsonHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303.json",
  "deckAnchorHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303#slide-38",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.34,
        "y": 0.81
      },
      "kind": "list",
      "text": "Suggest steady state achieved by day 14",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32c991da-2419-449f-9e99-05a8de1d20df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.34,
        "y": 0.42
      },
      "kind": "list",
      "text": "Data indicate CTI-1601 is generally well tolerated",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "877156f1-34d8-4b7c-87b6-fde7625d8445",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.62,
        "x": 0.34,
        "y": 0.48
      },
      "kind": "list",
      "text": "No serious adverse events. No important medical events. 1 severe adverse event (allergic reaction that resolved with standard treatment as referenced above).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1fa4dc0-05e9-402c-9442-9ff23a0db9d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.62,
        "x": 0.34,
        "y": 0.58
      },
      "kind": "list",
      "text": "The most common adverse events were mild and moderate injection site reactions (at least one injection site reaction was seen in 50% of placebo participants and in 100% of CTI-1601 participants)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad2a96e0-9f3a-45da-b03e-69a0d264ebe0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.62,
        "x": 0.34,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "25 mg CTI-1601 or placebo were administered subcutaneously daily for 14 days and then every other day until day 28. 13 participants were dosed in the trial (9 active, 4 placebo). Of the 9 CTI-1601-treated participants, 8 completed the trial with 1 withdrawing due to an allergic reaction to study drug, which resolved with standard treatment",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a17581d-6e90-4db6-ae92-a27841a32732",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.08,
        "y": 0.345
      },
      "kind": "title",
      "text": "CTI-1601 appeared to be generally well tolerated in Phase 2 trial's 25 mg cohort",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9957af38-e9b9-4de7-9b09-de3b64674569",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.34,
        "y": 0.14
      },
      "kind": "title",
      "text": "Summary of Phase 2 trial safety data (25 mg cohort):",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "311364a2-50e7-4209-aeed-d3e66fff429d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.34,
        "y": 0.75
      },
      "kind": "title",
      "text": "Pharmacokinetic Data",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c59d1e5-a705-473d-a913-ce52c8558ba8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "837879d8-65ba-4f63-b55d-8be446aedeaf",
      "evidence": "title/action-title: CTI-1601 appeared to be generally well tolerated in Phase 2 trial's 25 mg cohort",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 44,
      "from": 4,
      "beatId": "800ed350-717e-4cf5-a054-3d6626879633",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Multiple pages showcase clinical trial progress and data",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}